molecule Hsp90 inhibitor compounds for which crystallography has been published. This generally translates to interaction deep in the protein-binding pocket with the molecule remaining longer and thus inhibiting the protein for longer periods. Another major key differentiating point of the platform is that a subset of the library of over 500 molecules developed to date has the ability to cross the blood-brain barrier and the blood spinal cord barrier, making them particularly attractive candidate therapeutics for CNS indications, such as primary and secondary tumors of the CNS and neurodegenerative disorders.
Dr. Allan Rubenstein, NexGenix's CEO, said, "The grant of this US patent is part of a broad platform of intellectual property rights. NexGenix now has seven patent families allowed or pending covering the Company's compounds, various uses of these compounds, and other proprietary know-how. We believe that this matrix of intellectual property provides NexGenix with a unique position to benefit from the therapeutic applications of Hsp90 inhibitors."
The Company is currently in late stage pre-clinical development for its lead Hsp90 inhibitor with its unique ability to cross the blood-brain-barrier as a treatment for primary and metastatic brain tumors. NexGenix plans to seek regulatory approval to conduct a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of its lead Hsp90 inhibitor in advanced solid tumor malignancies.
About NexGenix: NexGenix Pharmaceuticals Inc. is a privately held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 500 potential compounds. From
Page: 1 2 3 4 5 Related medicine technology :1
|SOURCE NexGenix Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Landmark Patents Issued for ViewRay Technology2
. Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation3
. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling4
. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation5
. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions6
. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period7
. Rosetta Genomics Announces Issuance of Additional U.S. Patent8
. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film9
. IRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery10
. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid11
. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry